Heart failure is a global pandemic reported to affect at least 26 million people worldwide. Maximizing the inhibition of the renin-angiotensin-aldosterone system (RAAS) using optimally tolerated doses of inhibitors improves outcomes and reduces both morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF).
This case-based simulation will explore appropriate screening and monitoring strategies for patients with HFrEF as well as how to apply evidence-based approaches for maximizing guideline-recommended RAAS inhibitor therapies while managing potassium levels.
Facebook Comments